收费全文 | 394964篇 |
免费 | 34544篇 |
国内免费 | 15875篇 |
耳鼻咽喉 | 4076篇 |
儿科学 | 6555篇 |
妇产科学 | 4252篇 |
基础医学 | 63941篇 |
口腔科学 | 9500篇 |
临床医学 | 30631篇 |
内科学 | 60801篇 |
皮肤病学 | 7246篇 |
神经病学 | 26519篇 |
特种医学 | 9168篇 |
外国民族医学 | 156篇 |
外科学 | 31054篇 |
综合类 | 57294篇 |
现状与发展 | 68篇 |
一般理论 | 6篇 |
预防医学 | 20804篇 |
眼科学 | 5988篇 |
药学 | 47565篇 |
149篇 | |
中国医学 | 15113篇 |
肿瘤学 | 44497篇 |
2024年 | 1145篇 |
2023年 | 6993篇 |
2022年 | 14031篇 |
2021年 | 17803篇 |
2020年 | 14385篇 |
2019年 | 12719篇 |
2018年 | 12574篇 |
2017年 | 13049篇 |
2016年 | 13330篇 |
2015年 | 15267篇 |
2014年 | 23164篇 |
2013年 | 25908篇 |
2012年 | 22396篇 |
2011年 | 25607篇 |
2010年 | 21100篇 |
2009年 | 21119篇 |
2008年 | 21200篇 |
2007年 | 20507篇 |
2006年 | 18337篇 |
2005年 | 16416篇 |
2004年 | 14048篇 |
2003年 | 12319篇 |
2002年 | 9848篇 |
2001年 | 8356篇 |
2000年 | 7061篇 |
1999年 | 6336篇 |
1998年 | 5809篇 |
1997年 | 5345篇 |
1996年 | 4755篇 |
1995年 | 4202篇 |
1994年 | 3787篇 |
1993年 | 3198篇 |
1992年 | 2683篇 |
1991年 | 2482篇 |
1990年 | 2030篇 |
1989年 | 1789篇 |
1988年 | 1679篇 |
1987年 | 1406篇 |
1986年 | 1270篇 |
1985年 | 1811篇 |
1984年 | 1650篇 |
1983年 | 1151篇 |
1982年 | 1195篇 |
1981年 | 955篇 |
1980年 | 818篇 |
1979年 | 647篇 |
1978年 | 438篇 |
1977年 | 354篇 |
1976年 | 308篇 |
1975年 | 171篇 |
Background
Clear cell renal cell carcinoma (ccRCC) is known to occur across the adult lifetime traversing the spectrum of age-related organismal changes. Little is known as to how the aging process may affect the course of renal cell carcinoma (RCC) and the repertoire of genes involved.Methods
Using The Cancer Genome Atlas (n?=?436) and Cancer Genomics of the Kidney (n?=?89) datasets, we applied regression analysis to examine associations between patient age and gene expression profiles in ccRCC tumors and normal kidney tissues. Pathway enrichment analysis was performed to identify cellular process that is affected by aging in ccRCC. Moreover, connectivity mapping analysis was used to predict age-dependent response to drug treatments.Results
Our analysis revealed different age-dependent gene expression spectra in ccRCC and normal kidney tissues. These findings were significant and independently reproducible in both datasets examined. Age up-regulated genes, showing higher expression in older patients, were significantly enriched (false discovery rate <0.05) in normal tissues for pathways associated with immune response and extracellular matrix organization, whereas age up-regulated genes in tumors were enriched for metabolism and oxidation pathways. Strikingly, age down-regulated genes in normal cells were also enriched for metabolism and oxidation, while those in tumors were enriched for extracellular matrix organization. Further in silico analysis of potential drug targets predicted preferential efficacy of Phosphoinositide 3-kinase inhibitor or immunotherapy in association with age.Conclusion
We report on previously unrecognized associations between age and molecular underpinnings of RCC, including age-associated expression of genes implicated in RCC development or treatment. 相似文献Methods: This is a retrospective analysis of discharge records from the National Inpatient Sample database for patients receiving allo-HSCT between 1 January 2009 and 31 December 2013. Allo-HSCT discharges with an aGVHD diagnosis were included in the aGVHD group and those without any graft-versus-host disease (GVHD) diagnosis comprised the non-GVHD group. Mortality, LOS and costs were compared between the two groups, as well as within subgroups, including age (<18 vs. ≥18 years) and survival status (alive vs. deceased) at discharge.
Results: Overall, mortality (16.2% vs. 5.3%; p?<?.01), median hospital LOS (42.0 vs. 26.0 days; p?<?.01) and median total costs ($173,144 vs. $98,982; p?<?.01) were significantly increased in patients with aGVHD versus those without GVHD during hospitalizations for allo-HSCT, irrespective of age group. Patients with aGVHD who were <18 years of age had a lower mortality rate but greater hospital LOS and total costs versus patients aged ≥18 years. Patients who died during allo-HSCT hospitalization had longer LOS and incurred greater costs than those who survived in both the aGVHD and non-GVHD groups.
Conclusion: Occurrence of aGVHD during allo-HSCT admissions resulted in a tripling of the mortality rate and a near doubling of hospital LOS and total costs. In addition, death during allo-HSCT hospitalizations was associated with greater healthcare utilization and costs. Effectively mitigating aGVHD may improve survival and substantially reduce hospital LOS and costs for allo-HSCT. 相似文献